A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab)

被引：1
|
作者：
Cascinu, S. [1 ]
Lonardi, S. [2 ]
Rosati, G. [3 ]
Nasti, G. [4 ]
Zaniboni, A. [5 ]
Romiti, A. [6 ]
Aglietta, M. [7 ]
Bilancia, D.
Iaffaioli, V. [4 ]
Zagonel, V. [2 ]
Giordano, M. [8 ]
Corsi, D. [9 ]
Ferrau, F. [10 ]
Labianca, R. [11 ]
Berardi, R. [12 ]
Rulli, E. [13 ]
Floriani, I. [13 ]
机构：
[1] Azienda Osped Reg Torrette, Clin Oncol Med, Ancona, Italy
[2] Ist Oncol Veneto, UO Oncol Med, Padua, Italy
[3] Azienda Osped S Carlo, UO Oncol Med, Potenza, Italy
[4] INT IRCCS Fdn Pascale, UO Oncol Med, Naples, Italy
[5] Fdn Poliambulanza, UO Oncol Med, Brescia, Italy
[6] AOU Policlin St Andrea, UO Oncol Med, Rome, Italy
[7] Ist Candiolo IRCCS, UO Oncol Med, Candiolo, TO, Italy
[8] Osped St Anna, UO Oncol Med, Como, Italy
[9] Osped San Pietro Fatebenefratelli, UO Oncol Med, Rome, Italy
[10] Osped San Vincenzo, UO Oncol Med, Taormina, Italy
[11] Osped Papa Giovanni XXIII, UO Oncol Med, Bergamo, Italy
[12] Azienda Osped Reginale Torrette, Clin Oncol Med, Ancona, Italy
[13] Ist Ric Farmacol Mario Negri, Lab Ric Clin, Milan, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(15)30040-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2006
引用
收藏
页码：S329 / S329
页数：1
相关论文
共 50 条
  • [1] A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab
    Rosati, G.
    Nasti, G.
    Lonardi, S.
    Zaniboni, A.
    Romiti, A.
    Aglietta, M.
    Bilancia, D.
    Iaffaioli, V.
    Marsico, V.
    Giordano, M.
    Corsi, D.
    Ferrau, F.
    Labianca, R.
    Berardi, R.
    Galli, F.
    Frontini, L.
    Cascinu, S.
    ANNALS OF ONCOLOGY, 2015, 26 : 2 - 2
  • [2] A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab
    Cascinu, Stefano
    Rosati, Gerardo
    Nasti, Guglielmo
    Lonardi, Sara
    Zaniboni, Alberto
    Marchetti, Paolo
    Aglietta, Massimo
    Bilancia, Domenico
    Iaffaioli, Rosario Vincenz
    Zagonel, Vittorina
    Giordano, Monica
    Corsi, Domenico C.
    Ferrau, Francesco
    Labianca, Roberto
    Ronzoni, Monica
    Floriani, Irene Claudia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab.
    Cascinu, Stefano
    Zaniboni, Alberto
    Lonardi, Sara
    Rosati, Gerardo
    Nasti, Guglielmo
    Giordano, Monica
    Corsi, Domenico C.
    Ferrau, Francesco
    Iaffaioli, Rosario Vincenz
    Marchetti, Paolo
    Aglietta, Massimo
    Bilancia, Domenico
    Ronzoni, Monica
    Floriani, Irene Claudia
    Labianca, Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [4] Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients
    Cascinu, Stefano
    Rosati, Gerardo
    Nasti, Guglielmo
    Lonardi, Sara
    Zaniboni, Alberto
    Marchetti, Paolo
    Leone, Francesco
    Bilancia, Domenico
    Iaffaioli, Rosario Vincenzo
    Zagonel, Vittorina
    Giordano, Monica
    Corsi, Domenico C.
    Ferrau, Francesco
    Labianca, Roberto
    Ronzoni, Monica
    Scartozzi, Mario
    Galli, Francesca
    EUROPEAN JOURNAL OF CANCER, 2017, 83 : 106 - 115
  • [5] Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan plus Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer
    Sobrero, Alberto
    Lenz, Heinz-Josef
    Eng, Cathy
    Scheithauer, Werner
    Middleton, Gary
    Chen, Wenfeng
    Esser, Regina
    Nippgen, Johannes
    Burris, Howard
    ONCOLOGIST, 2021, 26 (02): : E261 - E269
  • [6] Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
    Pinto, C.
    Orlandi, A.
    Normanno, N.
    Maiello, E.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Pini, S.
    Bergamo, F.
    Tonini, G.
    Avallone, A.
    Latiano, T. P.
    Rosati, G.
    Pazzola, A.
    Ballestrero, A.
    Zaniboni, A.
    Roselli, M.
    Tamberi, S.
    Barone, C. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1390 - S1390
  • [7] Molecular profiling of the CAPRI GOIM trial in KRAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pts): Cetuximab plus FOLFIRI followed by FOLFOX4 ± cetuximab
    Ciardiello, F.
    Normanno, N.
    Maiello, E.
    Martinelli, E.
    Troiani, T.
    Rachiglio, A. M.
    Giuliani, F.
    Pisconti, S.
    Barone, C.
    Colucci, G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S14 - S14
  • [8] Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES study).
    Normanno, Nicola
    Rachiglio, Anna Maria
    Abate, Riziero Esposito
    Orlandi, Armando
    Maiello, Evaristo
    Maglietta, Giuseppe
    Damato, Angela
    Maiello, Monica Rosaria
    Carotenuto, Marianeve
    Calegari, Maria Alessandra
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria Giulia
    Tamberi, Stefano
    Lonardi, Sara
    Avallone, Antonio
    Latiano, Tiziana Pia
    Tamburini, Emiliano
    Barone, Carlo Antonio
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) (ERMES study)
    Normanno, Nicola
    Orlandi, Armando
    Maiello, Evaristo
    Rachiglio, Anna Maria
    Maglietta, Giuseppe
    Damato, Angela
    Calegari, Maria Alessandra
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria Giulia
    Tamberi, Stefano
    Lonardi, Sara
    Tonini, Giuseppe
    Rosati, Gerardo
    Latiano, Tiziana Pia
    Tamburini, Emiliano
    Maiello, Monica Rosaria
    Carotenuto, Marianeve
    Barone, Carlo
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Positive hyperselection of sensitizing genomic alterations (GAs) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES)
    Normanno, N.
    Rachiglio, A. M.
    Abate, R. Esposito
    Orlandi, A.
    Maiello, E.
    Maglietta, G.
    Damato, A.
    Maiello, M. R.
    Carotenuto, M.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Tamberi, S.
    Lonardi, S.
    Avallone, A.
    Latiano, T. P.
    Tamburini, E.
    Barone, C. A.
    Pinto, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S52 - S52
12345